A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies

[1]  Ian O Ellis,et al.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Johan Staaf,et al.  Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  N. Yamamoto,et al.  Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  Rafi Suzme,et al.  Serum tumor necrosis factor-alpha and interleukin-2 concentrations in newly diagnosed ERBB2 (HER2/neu) positive breast cancer patients. , 2009, The International journal of biological markers.

[5]  Jamie L. Harden,et al.  Central Role of Tumor-Associated CD8+ T Effector/Memory Cells in Restoring Systemic Antitumor Immunity1 , 2009, The Journal of Immunology.

[6]  R. Coombes,et al.  The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer , 2009, British Journal of Cancer.

[7]  R. Perret,et al.  Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours? , 2008, Tissue antigens.

[8]  H. Samonigg,et al.  Resistance to Apoptosis and Expansion of Regulatory T Cells in Relation to the Detection of Circulating Tumor Cells in Patients with Metastatic Epithelial Cancer , 2008, Journal of Clinical Immunology.

[9]  P. Haaland,et al.  Functional T Cell Responses to Tumor Antigens in Breast Cancer Patients Have a Distinct Phenotype and Cytokine Signature1 , 2007, The Journal of Immunology.

[10]  M. Lekander,et al.  NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy , 2007, British Journal of Cancer.

[11]  F. Montemurro,et al.  Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Menéndez,et al.  Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. , 2007, European journal of cancer.

[13]  S. Perez,et al.  CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu (HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients , 2007, Clinical Cancer Research.

[14]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[15]  Hailing Lu,et al.  IL-2 Immunotoxin Therapy Modulates Tumor-Associated Regulatory T Cells and Leads to Lasting Immune-Mediated Rejection of Breast Cancers in neu-Transgenic Mice1 , 2006, The Journal of Immunology.

[16]  S. Steinberg,et al.  A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  F. Penault-Llorca,et al.  Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? , 2006, British Journal of Cancer.

[18]  H. Fiegl,et al.  The Expression of the Regulatory T Cell–Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer , 2005, Clinical Cancer Research.

[19]  J. Becker,et al.  Spontaneous Immunity against Bcl-xL in Cancer Patients 1 , 2005, The Journal of Immunology.

[20]  J. Becker,et al.  Spontaneous T-cell responses against peptides derived from the Taxol resistance–associated gene-3 (TRAG-3) protein in cancer patients , 2005, Cancer Immunology, Immunotherapy.

[21]  J. Ioannidis,et al.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.

[22]  P. Coulie,et al.  Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen , 2005, The Journal of experimental medicine.

[23]  Roman Rouzier,et al.  Breast‐conserving surgery after neoadjuvant anthracycline‐based chemotherapy for large breast tumors , 2004, Cancer.

[24]  Timothy R. Crespin,et al.  Cellular Immunity in Breast Cancer Patients Completing Taxane Treatment , 2004, Clinical Cancer Research.

[25]  H. Fujii,et al.  Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes , 2004, Clinical Cancer Research.

[26]  E. van Marck,et al.  Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer , 2003, International journal of cancer.

[27]  M. Steurer,et al.  Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  J. Dipersio,et al.  Identification of HLA‐A3‐restricted CD8+ T cell epitopes derived from mammaglobin‐A, a tumor‐associated antigen of human breast cancer , 2002, International journal of cancer.

[29]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[30]  R. Dantzer,et al.  Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor. , 2002, Cancer research.

[31]  N. Tsavaris,et al.  Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes , 2002, British Journal of Cancer.

[32]  D. Schadendorf,et al.  Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. , 2002, Cancer research.

[33]  M. Salmon,et al.  EBV-Specific CD8+ T Cell Memory: Relationships Between Epitope Specificity, Cell Phenotype, and Immediate Effector Function1 , 2001, The Journal of Immunology.

[34]  J. Becker,et al.  Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. , 2001, Cancer research.

[35]  J. Lieberman,et al.  CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. , 2001, Blood.

[36]  E. Jaffee,et al.  Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. , 2001, Cancer research.

[37]  A. Tong,et al.  Cellular Immune Profile of Patients With Advanced Cancer Before and After Taxane Treatment , 2000, American journal of clinical oncology.

[38]  J. M. de Andrade,et al.  Lymphocyte Subpopulations in Patients with Advanced Breast Cancer Submitted to Neoadjuvant Chemotherapy , 2000, Tumori.

[39]  D. McNeel,et al.  Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer , 2000, Breast Cancer Research and Treatment.

[40]  Li-xi Yang,et al.  The immunological effects of taxanes , 2000, Cancer Immunology, Immunotherapy.

[41]  Ying Wang,et al.  IL-8 Reduced Tumorigenicity of Human Ovarian Cancer In Vivo Due to Neutrophil Infiltration1 , 2000, The Journal of Immunology.

[42]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[43]  D. Middleton,et al.  HLA-A towards a high-resolution DNA typing. , 1998, Tissue antigens.

[44]  F. Kwiatkowski,et al.  Primary chemotherapy in breast cancer: correlation between tumor response and patient outcome. , 1998, American journal of clinical oncology.

[45]  R. Henderson,et al.  MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines , 1995, Immunological reviews.

[46]  W. McGuire,et al.  HER-2/neu amplification predicts poor survival in node-positive breast cancer. , 1990, Cancer research.

[47]  P. Haaland,et al.  Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. , 2007, Journal of immunology.

[48]  P. Drew,et al.  Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). , 2006, Oncology reports.

[49]  Y. Morishita,et al.  Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report , 2000, Breast cancer.

[50]  S. Colombatto,et al.  Reduced IL-2 level concentration in patients with breast cancer as a possible risk factor for relapse. , 1996, European journal of gynaecological oncology.

[51]  C R King,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  M. Sherman,et al.  A Preliminary Report , 1953 .